SBI Contra Fund Direct Growth NAV Reaches ₹406.80 on 4 November 2026; Five-Year CAGR at 13.48%

Key Takeaways

• SBI Contra Fund Direct Growth recorded a NAV of ₹406.80 on 4 November 2026, representing a daily increase of 1.08% according to 5paisa.
• The latest performance data showed a one-year return of -6.49%, a three-year CAGR of 10.73% and a five-year CAGR of 13.48%.
• The scheme reported AUM of ₹45,068 crore and a Direct Growth expense ratio of 0.87%, with a minimum SIP amount of ₹500.
• TREPS represented the largest overall disclosed allocation at 6.40%, while HDFC Bank was the largest listed equity holding at 4.79%.

SBI Contra Fund Direct Growth recorded a net asset value of ₹406.80 on 4 November 2026. The refreshed 5paisa primary NAV card displayed a daily gain of 1.08% for the exact valuation date.

The latest historical performance snapshot showed a one-year return of -6.49%. The three-year annualised return stood at 10.73%, while the five-year CAGR was reported at 13.48%.

The five-year return exceeded the three-year figure by 2.75 percentage points. These are historical comparisons covering different trailing periods and do not represent the fund's one-day performance.

Assets under management stood at ₹45,068 crore, alongside a Direct Growth expense ratio of 0.87%. Minimum SIP and lump-sum investment amounts were displayed at ₹500 and ₹5,000, respectively.

SBI Contra Fund follows a contrarian equity investment strategy. This approach involves evaluating companies or market segments whose prevailing valuations or market perceptions may differ from the fund manager's assessment of their underlying fundamentals.

A contrarian classification does not eliminate equity-market exposure. Changes in company earnings, financial conditions and share prices continue to affect the scheme’s portfolio valuation.

The latest disclosed holdings showed TREPS as the largest overall entry at 6.40%. TREPS is a short-term money-market liquidity instrument rather than a listed equity security.

HDFC Bank was the largest listed equity holding at 4.79%, followed by Reliance Industries at 4.67%, ICICI Bank at 4.36% and Biocon at 3.29%.

The five largest disclosed entries, including TREPS, together represented 23.51% of the portfolio.

The reported beta stood at 0.97, with a Sharpe ratio of 0.37. These historical risk statistics describe earlier portfolio behaviour rather than subsequent NAV changes.

The verified ₹406.80 NAV relates specifically to 4 November 2026, while other fund information reflects the latest available disclosures.

Mutual Fund investments are subject to market risks, read all scheme related documents carefully.